PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING LIVER DISEASES COMPRISING CROMOLYN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS EFFECTIVE INGREDIENTS
To provide pharmaceutical compositions for preventing and treating liver diseases such as cirrhosis, liver fibrosis, liver failure, liver cancer and hepatitis.SOLUTION: Disclosed herein is a pharmaceutical composition for preventing and treating liver diseases comprising cromolyn of the following formula or a pharmaceutically acceptable salt thereof.EFFECT: Cromolyn or its pharmaceutically acceptable salt inhibits the accumulation of collagen and the production of TGF-β in hepatic stellate cells (HSCs), and also suppresses hepatocyte migration caused by TGF-β. Further, it inhibits the decrease of E-cadherin expression resulting from epithelial mesenchymal transition progression and has an anti-senescence effect on hepatocytes. As a result, cromolyn has the dual effect of inhibiting the activity of HSCs and promoting the recovery of hepatocyte function, and thus can be used as a fundamental therapeutic agent for various liver diseases including liver cirrhosis.SELECTED DRAWING: Figure 5【課題】肝硬変、肝線維症、肝不全、肝癌、及び肝炎等の肝疾患の予防及び治療用薬学的組成物の提供。【解決手段】クロモリン（下式）又はこれの薬学的に許容可能な塩を有効成分として含有する肝疾患の予防及び治療用薬学的組成物。【効果】肝星状細胞（ＨＳＣ細胞）においてコラーゲンの蓄積及びＴＧＦ－βの生成を抑制するだけでなく、肝細胞でＴＧＦ－β処理による肝細胞の移動を抑制し、上皮間葉移行進行によるＥ－カドヘリンの発現の減少を抑制し、肝細胞の抗老化効果を奏するので、ＨＳＣ細胞の活性を抑制する効果を奏するだけでなく、肝細胞の機能を回復させる二重の効果を奏するので、肝硬変症を含む多様な肝臓疾患の根本的な治療剤として用いられ得る。【選択図】図５
